stockrowBeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) Net income
BeOne Medicines Ltd. - Sponsored ADR's net income for fiscal 2025 was $286.9M, compared with −$644.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $915.6M. Over the past ten years it has ranged from −$2.0B (fiscal 2022) to $286.9M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 3 consecutive fiscal years. BeOne Medicines Ltd. - Sponsored ADR ranks 7th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $286.9M | — |
| FY2024 | −$644.8M | — |
| FY2023 | −$881.7M | — |
| FY2022 | −$2.0B | — |
| FY2021 | −$1.5B | — |
| FY2020 | −$1.6B | — |
| FY2019 | −$950.6M | — |
| FY2018 | −$674.0M | — |
| FY2017 | −$93.3M | — |
| FY2016 | −$119.2M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $384.7M | 62.32% |
| Jun 2026 | $237.0M | 4.24% |
| Mar 2026 | $227.4M | 241.88% |
| Dec 2025 | $66.5M | (46.73%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ARGX argenex SE compare | $1.6B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| ONC BeOne Medicines Ltd. - Sponsored ADR | $915.6M |
| GMAB Genmab A/S Sponsored ADR compare | $906.0M |
| INCY Incyte Corporation compare | $403.4M |
| ROIV Roivant Sciences Ltd. compare | −$414.6M |
| INSM Insmed, Inc. compare | −$605.6M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.6B |
| RVMD Revolution Medicines, Inc. compare | −$1.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ONC
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement